Court Place Advisors LLC Sells 77,445 Shares of OmniAb, Inc. (NASDAQ:OABI)

Court Place Advisors LLC reduced its stake in OmniAb, Inc. (NASDAQ:OABI - Free Report) by 76.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 23,556 shares of the company's stock after selling 77,445 shares during the quarter. Court Place Advisors LLC's holdings in OmniAb were worth $83,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. CWC Advisors LLC. acquired a new position in shares of OmniAb during the third quarter worth approximately $54,000. Walleye Capital LLC bought a new position in shares of OmniAb during the 3rd quarter worth about $61,000. Intech Investment Management LLC acquired a new position in shares of OmniAb during the third quarter valued at about $70,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of OmniAb by 64.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company's stock valued at $96,000 after buying an additional 8,909 shares during the period. Finally, Palumbo Wealth Management LLC grew its position in OmniAb by 12.5% during the third quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company's stock worth $104,000 after buying an additional 2,744 shares in the last quarter. Institutional investors and hedge funds own 72.08% of the company's stock.

Analyst Ratings Changes

A number of brokerages have commented on OABI. Benchmark reiterated a "buy" rating and issued a $8.00 price objective on shares of OmniAb in a research report on Thursday, November 14th. HC Wainwright reaffirmed a "buy" rating and issued a $11.00 target price on shares of OmniAb in a research report on Thursday, November 14th.

OmniAb Stock Performance

Shares of OABI stock traded up $0.01 during trading hours on Friday, hitting $3.22. The company had a trading volume of 492,770 shares, compared to its average volume of 501,138. The firm has a market capitalization of $454.73 million, a price-to-earnings ratio of -5.19 and a beta of -0.10. OmniAb, Inc. has a 12 month low of $3.10 and a 12 month high of $6.55. The firm's fifty day moving average is $3.60 and its 200 day moving average is $4.02.

Insiders Place Their Bets

In other OmniAb news, CEO Matthew W. Foehr sold 41,811 shares of the company's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total transaction of $135,467.64. Following the transaction, the chief executive officer now directly owns 3,749,639 shares in the company, valued at approximately $12,148,830.36. This represents a 1.10 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Charles S. Berkman sold 25,489 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total transaction of $82,584.36. Following the completion of the transaction, the insider now owns 343,190 shares in the company, valued at $1,111,935.60. This represents a 6.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 82,826 shares of company stock worth $268,356 over the last three months. 8.60% of the stock is currently owned by corporate insiders.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.